Objective The aim of this study was to determine the suitable treatment period in patients who achieve virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C virus infection. 
Introduction

Current evidence indicates that combination therapy of peginterferon and ribavirin for hepatitis C virus (HCV) is associated with a higher rate of sustained virological response (SVR) compared with interferon (IFN) alone
. This indicates that patients with RVR should be treated for a short course-regimen. In contrast, it may be necessary to treat patients without RVR using a long courseregimen.
The selection of duration of treatment and optimum doses of combination therapy is an area of active investigation (9) (10) (11) (12) (13) (14) (15) Table 1 . There was a significant difference in the serum level of HCV RNA before treatment among the four groups classified based on the difference of response. (8, 20, 21) . The present results coincided closely with these earlier results.
Materials and Methods
Patients
Statistical analysis
Clinical and biochemical backgrounds before combination therapy among groups based on efficacy of treatment were analyzed using Krusukall Wallis test. We used multivariate analysis (multiple logistic regression analysis) to establish which factors contributed to the non-relapse after combina
Results
Clinical characteristics of the patients
A total of 366 patients were enrolled in the present study. Patients were classified into four groups according to the difference of response: RVR (n=37), EVR (n=161), LVR (n=131), and SLVR (n=37). The clinical and laboratory characteristics of the patients at baseline are shown in
Predictors of non-relapse in patients
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EVR, and 60 weeks in LVR.
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